Literature DB >> 2968449

Characterization of [5,6-3H]SQ 29,548 as a high affinity radioligand, binding to thromboxane A2/prostaglandin H2-receptors in human platelets.

A Hedberg1, S E Hall, M L Ogletree, D N Harris, E C Liu.   

Abstract

The binding of 5,6-3H(1S-[1 alpha, 2 beta(5Z), 3 beta, 4 alpha])-7-[3-([2-[(phenyl amino)carbonyl]hydrazino]methyl)-7-oxabicyclo[2.2.1]hept-2-yl]-5- heptenoic acid to receptors in human washed platelets (WP) and platelet membranes (PM) was characterized with regard to kinetics, saturability and competitive inhibition by putative thromboxane A2/prostaglandin H2 (TP)-receptor ligands. Specific binding of [3H]SQ 29,548 routinely amounted to 90 to 97% of total binding. The rate of association was 1.6 x 10(7) and 2.5 x 10(7) M-1 x min-1 in WP and PM, respectively. The corresponding rate of dissociation was 0.07 and 0.12 min-1, resulting in dissociation constants of 4.1 and 5.8 nM in WP and PM, respectively. Saturable binding to a single class of receptors indicated a receptor density of 2633 fmol/mg of protein in WP (1394 receptors/platelet; kd, 4.5 nM) and 1466 fmol/mg of protein in PM (kd, 11.3 nM). Specific binding of [3H]SQ 29,548 was inhibited by five antagonists (high/low affinity kd values in nanomolar), SQ 29,548 (WP, 5.2; PM, 7.3), SQ 28,668 (WP, 32; PM, 73), SQ 30,741 (WP, 28; PM, 50), BM 13,177 (WP, 140; PM, 4834) and BM 13,505 (WP, 5/379; PM, 11). Two agonists, U 44069 and U 46619, inhibited the binding in a biphasic manner, indicating binding to two receptor sites (approximately 20/80%) with kd values of 4/72 and 4/170 nM, respectively, in WP and 7/136 and 19/502 nM, respectively in PM. The demonstrated high affinity binding of [3H]SQ 29,548 to human platelet TP-receptors should make this radioligand a suitable and potentially useful tool in future studies of function, structure and regulation of TP-receptors.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2968449

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  14 in total

1.  Bombesin, neuromedin B and neuromedin C interact with a common rat pancreatic phosphoinositide-coupled receptor, but are differentially regulated by guanine nucleotides.

Authors:  M C Sekar; N Uemura; D H Coy; B I Hirschowitz; K E Dickinson
Journal:  Biochem J       Date:  1991-11-15       Impact factor: 3.857

2.  A molecular mechanism for signaling between seven-transmembrane receptors: evidence for a redistribution of G proteins.

Authors:  Y Djellas; K Antonakis; G C Le Breton
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

3.  Distinct biochemical properties of the native members of the G12 G-protein subfamily. Characterization of G alpha 12 purified from rat brain.

Authors:  R Harhammer; B Nürnberg; C Harteneck; D Leopoldt; T Exner; G Schultz
Journal:  Biochem J       Date:  1996-10-01       Impact factor: 3.857

4.  Characteristics of the binding of [3H]-GR32191 to the thromboxane (TP-) receptor of human platelets.

Authors:  R A Armstrong; P P Humphrey; P Lumley
Journal:  Br J Pharmacol       Date:  1993-10       Impact factor: 8.739

5.  Brain changes associated with thromboxane receptor antagonist SQ 29,548 treatment in a mouse model.

Authors:  Andrew A Rebel; Siri A Urquhart; Kendra L Puig; Atreyi Ghatak; Stephen A Brose; Mikhail Y Golovko; Colin K Combs
Journal:  J Neurosci Res       Date:  2015-02-22       Impact factor: 4.164

Review 6.  TP receptors and oxidative stress hand in hand from endothelial dysfunction to atherosclerosis.

Authors:  Michel Félétou; Richard A Cohen; Paul M Vanhoutte; Tony J Verbeuren
Journal:  Adv Pharmacol       Date:  2010

7.  Involvement of central beta2-adrenergic, NMDA and thromboxane A2 receptors in the pressor effect of anandamide in rats.

Authors:  B Malinowska; A Zakrzeska; C M Kurz; M Göthert; G Kwolek; P Wielgat; J J Braszko; E Schlicker
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-03-03       Impact factor: 3.000

Review 8.  Prostanoid receptor antagonists: development strategies and therapeutic applications.

Authors:  R L Jones; M A Giembycz; D F Woodward
Journal:  Br J Pharmacol       Date:  2009-07-15       Impact factor: 8.739

9.  Thromboxane-insensitive dog platelets have impaired activation of phospholipase C due to receptor-linked G protein dysfunction.

Authors:  G J Johnson; L A Leis; P C Dunlop
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

10.  Dietary fat modifies thromboxane A2-induced stimulation of rat platelets.

Authors:  J W Heemskerk; M A Feijge; A Kester; G Hornstra
Journal:  Biochem J       Date:  1991-09-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.